Black Rock Inc. Infinity Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.14 - $0.24 $49 - $84	352 Added 0.02%	1,461,881 $306,000
Q1 2023 May 12, 2023	SELL	$0.16 - $0.74 $19,823 - $91,681	-123,894 Reduced 7.81%	1,461,529 $233,000
Q4 2022 Feb 13, 2023	SELL	$0.46 - $1.21 $319,803 - $841,221	-695,224 Reduced 30.48%	1,585,423 $887,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $14,655 - $42,226	-24,839 Reduced 1.08%	2,280,647 $2.71 Million
Q2 2022 Aug 12, 2022	SELL	$0.49 - $1.2 $2.09 Million - $5.12 Million	-4,263,924 Reduced 64.91%	2,305,486 $1.46 Million
Q1 2022 May 12, 2022	SELL	$0.85 - $2.4 $83,379 - $235,423	-98,093 Reduced 1.47%	6,569,410 $7.49 Million
Q4 2021 Feb 10, 2022	BUY	$1.86 - $3.36 $1.27 Million - $2.3 Million	684,014 Added 11.43%	6,667,503 $15 Million
Q3 2021 Nov 09, 2021	SELL	$1.52 - $3.82 $87,939 - $221,006	-57,855 Reduced 0.96%	5,983,489 $20.5 Million
Q2 2021 Aug 11, 2021	BUY	$2.66 - $3.47 $16.1 Million - $21 Million	6,041,344 New	6,041,344 $18.1 Million

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.